Filter posts

The Administration’s Orwellian Defense of Importing Foreign Price Controls

The Trump administration is out with a new blog post defending its plan to adopt …

Greenwood Talks Innovation, Drug Pricing, and the Midterm Elections on ForbesBooks Radio

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks …

Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate …

Another Year, Another Misleading Insurance Company Report

Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear …

Watchdog Report Reaffirms Concerns With Fail First

A new report by the Office of Inspector General at the U.S. Department of Health …

Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit …

Hits to Patients Keep on Coming

At a time when prescription drug prices and spending are remarkably stable, patients are getting …

PBS NewsHour: Why a Patient Paid a $285 Copay for a $40 Drug

A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine …

As Out-of-Pocket Costs Rise, Insurers Spend Big on Administrative Costs

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators …

Debunking a Common Myth on Out-of-Pocket Costs

The facts continue to show that, when it comes to prescription drug costs, the country …